BioMarin Pharmaceutical

Ultime notizie

Titoli nella lingua originale della fonte.

• What BioMarin Pharmaceutical (BMRN)'s AI Drug Discovery Deal Means For Shareholders (si apre in una nuova scheda)

  Simply Wall Street · 2 ott 2026

• After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. (si apre in una nuova scheda)

  Stock Titan · 1 ott 2026

• The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) (si apre in una nuova scheda)

  Yahoo Finance · 1 ott 2026

• BioMarin and Profluent partner on AI-designed enzyme therapies (si apre in una nuova scheda)

  Pharmaceutical Technology · 1 ott 2026

• BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration (si apre in una nuova scheda)

  Simply Wall Street · 1 ott 2026

• BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth (si apre in una nuova scheda)

  AD HOC NEWS · 30 set 2026

• Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 (si apre in una nuova scheda)

  TradingView · 30 set 2026

• BioMarin Grants Ascendis Global License, Secures Royalty Revenues (si apre in una nuova scheda)

  tipranks.com · 30 set 2026

• BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 (si apre in una nuova scheda)

  TradingView · 30 set 2026

• BioMarin lays off 117 California workers to consolidate footprint (si apre in una nuova scheda)

  Fierce Pharma · 30 set 2026

• Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI (si apre in una nuova scheda)

  marketscreener.com · 30 set 2026

• Profluent Partners With BioMarin to Design Novel Medicines Using AI (si apre in una nuova scheda)

  Business Wire · 30 set 2026

• Layoff Tracker: Novo, BioMarin, Enanta dole out pink slips (si apre in una nuova scheda)

  BioSpace · 30 set 2026

• BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board (si apre in una nuova scheda)

  Simply Wall Street · 26 set 2026

• BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish (si apre in una nuova scheda)

  AD HOC NEWS · 23 set 2026

• BioMarin Pharmaceutical stock holds near its 52-week low (si apre in una nuova scheda)

  AD HOC NEWS · 22 set 2026

• BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) (si apre in una nuova scheda)

  Seeking Alpha · 21 set 2026

• BioMarin Pharmaceutical stock holds near a $12.38 billion value (si apre in una nuova scheda)

  AD HOC NEWS · 20 set 2026

• What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? (si apre in una nuova scheda)

  Yahoo Finance · 19 set 2026

• BioMarin stock steadies after September 17 close (si apre in una nuova scheda)

  AD HOC NEWS · 18 set 2026

• BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone (si apre in una nuova scheda)

  Yahoo Finance · 18 set 2026

• What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders (si apre in una nuova scheda)

  Simply Wall Street · 17 set 2026

• BioMarin Pharmaceutical Grants Director Robert M Plenge 6,140 Shares at No Cost (NASDAQ: BMRN) (si apre in una nuova scheda)

  Kalkine Media · 15 set 2026

• BioMarin's stock target raised to $97 after pos... (si apre in una nuova scheda)

  Pluang · 15 set 2026

• BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts (si apre in una nuova scheda)

  Fierce Pharma · 15 set 2026

• Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com (si apre in una nuova scheda)

  Investing.com India · 14 set 2026

• BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors (si apre in una nuova scheda)

  PR Newswire · 14 set 2026

• BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units (si apre in una nuova scheda)

  Stock Titan · 14 set 2026

• BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board (si apre in una nuova scheda)

  TradingView · 14 set 2026

• BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board (si apre in una nuova scheda)

  citybiz.co · 14 set 2026